A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients
- 17 Downloads
In an open, randomized, two-centre, cross-over study 20 patients formerly adjusted to a stable oral twice daily 200–600 mg carbamazepine dose, used ordinary tablets and divitabs (a new sustained-release formulation) for periods of three weeks, whereafter the serum level courses of carbamazepine and its metabolite carbamazepine-10,ll-epoxide were measured. The mean peak/mean trough carbamazepine-serum concentration ratio was slightly lower after the intake of divitabs in comparison to normal formulation: 1.14±0.447 versus 1.23±0.545 (mean ±SD). The mean trough levels of carbamazepine and its metabolite were 9% and 16% lower in the case of divitabs. In patients with peak/trough carbamazepine-serum level ratios of at least 1.30 after the intake of normal formulation, divitabs had a significant advantage.
KeywordsBiopharmaceutics Carbamazepine Clinical trials Drug compounding Pharmacokinetics Tablets Tablets, controlled release
Unable to display preview. Download preview PDF.
- 1.Schobben AFAM. Pharmacokinetics and therapeutics in epilepsy. Nijmegen: Catholic University of Nijmegen, 1979. Dissertation.Google Scholar
- 2.Sillanpää M. Carbamazepine. Pharmacology and clinical uses. Acta Neurol Scand 1981;64(suppl 88).Google Scholar
- 12.Nolen WA, Jansen GS, Broekman M. Measuring plasma levels of carbamazepine; a pharmacokinetic study in patients with affective disorders. Pharmacopsychiatria 1988;21:252–4.Google Scholar
- 13.Loonen AJM, Zwanikken GJ. Farmaca, Psychofarmaca, Klinisch onderzoek. Ontwikkeling, beproeving en toepassing van (psycho)farmaca. 's-Hertogenbosch: WULCO, 1987.Google Scholar
- 14.Siegel S. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956.Google Scholar